Skip to main content

ADMA Biologics Value Stock - Dividend - Research Selection

Adma biologics

ISIN: US0008991046 , WKN: A12FAG

Market price date:
Market price:  


Fundamental data and company key figures of the share

Annual reports in
Key figures
Cash flow
Net operating cash flow
Capital Expenditures
Free cash flow
Balance sheet
Total Equity
Liabilities & Shareholders equity
Income statement
Net income
Eps (diluted)
Diluted shares outstanding
Net sales/revenue

Fundamental ratios calculated on:

Ratios
Key figures
Cash flow
P/C
 
P/FC
Balance sheet
ROI
ROE
Income statement
P/E
Div. Yield %
P/B
P/S


Do you want to do make a detailed fundamental analysis of this stock?

✓ NEW Fundamental API Access to 500 data points per month
Fundamental data up to 25 years
Comparison to all other stocks by the FScore
Time saving!

How our site works ...

Non-binding 7 days without automatic subscription
 No termination required after the free week
Finanzoo fundamental analysis
Data updated daily
Virtual depots
Share alarms via email
Subscription can be canceled at any time at the end of the month 
Choice of desired shares
Over 2000 stock analyzes available
Bitcoin payment possible if you do not want to subscribe

Price for monthly subscription $ 19.99 / month including VAT.



Description Data
Symbol
Market Capitalization USD
Country
Indices
Sectors
Raw Data Source
Stock Split
Internet


Description of the company

ADMA Biologics, Inc., a biopharmaceutical and specialty immunoglobulin company, develops, manufactures, and markets specialty plasma-derived biologics for the treatment of immune deficiencies and infectious diseases in the United States. It offers BIVIGAM, an intravenous immune globulin product indicated for the treatment of primary humoral immunodeficiency (PI); ASCENIV, an IVIG product for the treatment of PI; and Nabi-HB, which is indicated for the treatment of acute exposure to blood containing Hepatitis B surface antigen and other listed exposures to Hepatitis B. It also develops a pipeline of plasma-derived therapeutics, including products related to the methods of treatment and prevention of S. pneumonia infection for an immunoglobulin. In addition, the company operates source plasma collection facilities. The company distributes its products through independent distributors, sales agents, specialty pharmacies, and other alternate site providers. ADMA Biologics, Inc. was founded in 2004 and is headquartered in Ramsey, New Jersey.

The Finanzoo GmbH assumes no liability for the accuracy of the information! All information is provided without warranty. Sources:: www.bundesanzeiger.de, www.sec.gov,


NEWS


Chart Of The Day: ADMA Biologics - Hitting New Highs

2024-05-06
Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

Adma Biologics (ADMA) Rises Higher Than Market: Key Facts

2024-05-02
Adma Biologics (ADMA) reachead $6.74 at the closing of the latest trading day, reflecting a +1.05% change compared to its last close.

ADMA Biologics to Report First Quarter 2024 Financial Results on May 9, 2024

2024-05-02
Conference Call Scheduled for May 9, 2024, at 4:30 p.m. ETRAMSEY, N.J. and BOCA RATON, Fla., May 02, 2024 (GLOBE NEWSWIRE) -- ADMA Biologics, Inc. (Nasdaq: ADMA) (“ADMA” or the “Company”), an end-to-end commercial biopharmaceutical company dedicated to manufacturing, marketing, and developing specialty biologics, today announced that it will report first quarter 2024 financial results on May 9, 2024, after the U.S. financial markets close. ADMA’s management team will host a live conference call

Adma Biologics (ADMA) Is Considered a Good Investment by Brokers: Is That True?

2024-04-30
Based on the average brokerage recommendation (ABR), Adma Biologics (ADMA) should be added to one's portfolio. Wall Street analysts' overly optimistic recommendations cast doubt on the effectiveness of this highly sought-after metric. So, is the stock worth buying?

What's in Store for ADMA Biologics (ADMA) in Q1 Earnings?

2024-04-29
On ADMA Biologics' (ADMA) first-quarter 2024 earnings call, investors' focus is likely to be on the sales performance of its marketed products, Bivigam, Asceniv and Nabi-HB.

Beat the Market the Zacks Way: ADMA Biologics, Carlisle, McCormick Manufacturing in Focus

2024-04-29
Our time-tested methodologies were at work to help investors navigate the market well last week. Here are some of our key performance data from the past three months.

3 'Buy-Rated' Biotech Stocks Under $10

2024-04-28
All three small-cap biotech/biopharma stocks have attractive risk/reward profiles and potential catalysts on the horizon. Click here for the complete stock list.

Adma Biologics (ADMA) Stock Moves -0.31%: What You Should Know

2024-04-25
In the most recent trading session, Adma Biologics (ADMA) closed at $6.44, indicating a -0.31% shift from the previous trading day.

Biotech Alert: Searches spiking for these stocks today

2024-04-25
Looking for stock market analysis and research with proves results? Zacks.com offers in-depth financial research with over 30years of proven results.

Recent Price Trend in Adma Biologics (ADMA) is Your Friend, Here's Why

2024-04-24
Adma Biologics (ADMA) could be a great choice for investors looking to make a profit from fundamentally strong stocks that are currently on the move. It is one of the several stocks that made it through our "Recent Price Strength" screen.